Chiaravalli A M, Furlan D, Facco C, Tibiletti M G, Dionigi A, Casati B, Albarello L, Riva C, Capella C
Department of Pathology, Hospital Fondazione Macchi, Varese, Italy.
Virchows Arch. 2001 Jan;438(1):39-48. doi: 10.1007/s004280000325.
Alterations of DNA mismatch repair (MMR) genes are involved in carcinogenesis of sporadic and inherited human cancers characterised by instability of DNA microsatellite sequences (MSI). MSI tumours are usually identified using molecular analysis. In the present investigation, hMLH1 and hMSH2 immunohistochemistry was tested in order to evaluate the utility of this method in predicting MMR deficiency. Colorectal (72), gastric (68), endometrial (44) and ovarian (17) carcinomas were independently evaluated for familial history, histological type of tumour, MSI status and immunohistochemical results. Loss of expression of either hMLH1 or hMSH2 was observed in 51 of 55 (92.8%) MSI tumours, while 145 of 146 microsatellite stable (MSS) tumours expressed both the hMLH1 and hMSH2 gene products. Independently of tumour site, an overall agreement between immunohistochemical and molecular results was observed in 15 hereditary non-polyposis colorectal cancer-related tumours. Among sporadic tumours, only 2 of 60 colorectal and 2 of 66 gastric carcinomas, displaying MSI, expressed both hMLH1 and hMSH2 gene products. All 39 endometrial and 16 ovarian tumours presented a concordant molecular and immunohistochemical profile. These data show that immunohistochemistry is an accurate and rapid method to predict the presence of defective DNA MMR genes and to identify both sporadic and familial MSI tumours.
DNA错配修复(MMR)基因的改变参与了以DNA微卫星序列(MSI)不稳定为特征的散发性和遗传性人类癌症的致癌过程。MSI肿瘤通常通过分子分析来鉴定。在本研究中,检测了hMLH1和hMSH2免疫组织化学,以评估该方法在预测MMR缺陷中的效用。对72例结直肠癌、68例胃癌、44例子宫内膜癌和17例卵巢癌独立评估家族史、肿瘤组织学类型、MSI状态和免疫组织化学结果。在55例MSI肿瘤中的51例(92.8%)中观察到hMLH1或hMSH2表达缺失,而146例微卫星稳定(MSS)肿瘤中的145例同时表达hMLH1和hMSH2基因产物。在15例遗传性非息肉病性结直肠癌相关肿瘤中,无论肿瘤部位如何,免疫组织化学和分子结果之间总体一致。在散发性肿瘤中,60例结直肠癌和66例胃癌中只有2例显示MSI,同时表达hMLH1和hMSH2基因产物。所有39例子宫内膜癌和16例卵巢癌均呈现一致的分子和免疫组织化学特征。这些数据表明,免疫组织化学是一种准确、快速的方法,可用于预测DNA MMR基因缺陷的存在,并识别散发性和家族性MSI肿瘤。